whatshot

QTNTQ   $0.039  14.71% Market Closed

show_chart Advanced Chart of QTNTQ
Last Events:

2023-07-18 Trend pattern changed from нисходящий клин to канал.

2023-05-20 Trend pattern changed from не определен to нисходящий клин.

2023-05-20 Signal in Stochastic changed from не определен to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: main and signal line crossing.

2023-05-20 Signal in MACD changed from не определен to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-05-20 Signal in RSI changed from не определен to bearish. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: exit from the overbought zone.

2023-05-20 Signal in EMA100 changed from не определен to n/a.

2023-05-20 Signal in EMA50 changed from не определен to bearish reversal. 2023-05-18 the price crossed down the moving average line and formed a short-term downside trend.

2023-05-20 Signal in EMA20 changed from не определен to n/a. 2023-05-18 the price crossed down the moving average line and formed a short-term downside trend.

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 1
Target Price Mean 60.00
Mean unverified/preliminary 60.00 / 60.00
Target Price Low / High 60.00 / 60.00
Median / STD DEV 60.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total - Sell -
rsi ActivelyBuy - -
macd - - -
stoch - - -
ma20 - Sell -
ma50 - - -
ma100 Sell - -
ISIN JE00BNNSZY03
ceo Mr. Manuel O. Mendez
Website https://www.quotientbd.com
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.